STEVEN I SHERMAN to Pyrroles
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Pyrroles.
Connection Strength
0.202
-
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Ann Oncol. 2013 Sep; 24(9):2256-61.
Score: 0.081
-
Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec; 23(6):713-22.
Score: 0.064
-
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ. 2015 Mar; 18(3):200-9.
Score: 0.023
-
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother. 2011 Jul; 12(10):1491-7.
Score: 0.018
-
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95.
Score: 0.016